Genotype-guided treatment of oral P2Y(12) inhibitors: where do we stand?

Daniel M. F. Claassens, Jurrien M. ten Berg*

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

5 Citations (Scopus)
Original languageEnglish
Pages (from-to)83-86
Number of pages4
JournalPharmacogenomics
Volume21
Issue number2
Early online date20-Jan-2020
DOIs
Publication statusPublished - 2020

Keywords

  • acute coronary syndrome
  • clopidogrel
  • CYP2C19
  • genotype-guided
  • myocardial infarction
  • P2Y12 inhibitor
  • prasugrel
  • ticagrelor
  • ANTIPLATELET TREATMENT
  • CYP2C19 GENOTYPE
  • TASK-FORCE
  • CLOPIDOGREL
  • GUIDELINES
  • MANAGEMENT
  • THERAPY

Cite this